Diligence memo · auto-generated · as of July 2, 2026
Med Aditus Pharmaceuticals, Inc.
Med Aditus Pharmaceuticals, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Med Aditus Pharmaceuticals, Inc. operates in Pharmaceuticals, based in RTP.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Med Aditus Pharmaceuticals, Inc. has raised $5.0M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.0M on 2024-11-06.
Most recent recorded round closed around 2024-11-06.
Valuation (modeled)modeled
Provath models Med Aditus Pharmaceuticals, Inc. at approximately $22M (range $5.7M–$44M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.67× the median modeled value of Series A Pharmaceuticals companies in 2022–2024 (64 peers) — value vs value, same stage and era. Within the normal band (67% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 20 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 42% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 29% of those peers.
Closest niche peers: Hallux, Inc., Enalare Therapeutics Inc., Silver Creek Pharmaceuticals, Inc., NQ PE Project Stingray Parent, L.P., Acta Pharmaceuticals, Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.